Healthleap
AI platform analyzing hospital records to identify inpatients at risk of missed or undiagnosed conditions.
Website: https://healthleap.ai
Cover Block
Publicly reported
| Field | Value |
|---|---|
| Company | Healthleap |
| Tagline | AI platform analyzing hospital records to identify inpatients at risk of missed or undiagnosed conditions [TechCrunch, October 2026] |
| Headquarters | San Francisco, California, United States [Healthleap, October 2026] |
| Founded | 2022 [TechCrunch, January 2022] |
| Stage | Series A [TechCrunch, October 2026] |
| Business Model | SaaS |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+): Josiah Meyer, Jemima Meyer, Ray Botha [TechCrunch, January 2022] |
| Funding Label | Series A, total disclosed $39.1 million [TechCrunch, January 2022] [TechCrunch, October 2026] |
Links
Publicly reported
- Website: https://healthleap.ai
- Careers: https://healthleap.ai/careers
Summary and Signal
PUBLIC Healthleap sells clinical AI software to hospitals that reads electronic health records and flags inpatients who may have missed or undiagnosed conditions, a proposition that has become more relevant as the company reports deployment across more than 50 hospitals and closes a combined $38 million seed and Series A financing in October 2026 [TechCrunch, October 2026]. The founding story is unusually tight for this category: the company began with a malnutrition-focused tool built by co-founder Jemima Meyer, then expanded into a broader inpatient-risk detection platform that now includes conditions such as malnutrition and delirium [TechCrunch, January 2022] [TechCrunch, October 2026].
The product differentiation, as described in public reporting, rests less on a general model layer and more on workflow fit inside the hospital record system, where the software is meant to surface patients who need additional clinical attention before those cases are missed by standard screening processes [TechCrunch, October 2026]. A company-linked clinical claim says its screening system was 88% more sensitive than nursing-administered manual screening for high-risk malnutrition patients, but that evidence appears in LinkedIn-sourced materials rather than independent peer-reviewed publication, so it should be treated as directional rather than settled [LinkedIn, 2026].
The founding bench combines clinical and product backgrounds. Jemima Meyer is identified as a clinical dietitian and the builder of NutriLeap, the precursor product, while Josiah Meyer is identified as co-founder and CEO with prior product and strategy roles at Yellow Card App, Invictus Capital, and Boston Consulting Group; Ray Botha is publicly identified as co-founder and CTO in early coverage [TechCrunch, October 2026] [RocketReach, 2026] [TechCrunch, January 2022].
On capitalization, the public record shows a $1.1 million pre-seed led by Fifty Years in January 2022, followed by an $8 million seed co-led by Sequoia Capital and First Round Capital and a $30 million Series A led by Hummingbird Ventures in October 2026, for roughly $39.1 million in disclosed funding to date [TechCrunch, January 2022] [TechCrunch, October 2026]. The business model is SaaS sold to hospitals and health systems, which is attractive if Healthleap can convert early deployment breadth into durable enterprise contracts inside conservative provider workflows [TechCrunch, October 2026].
Over the next 12 to 18 months, the key public markers to watch are whether deployment count converts into deeper penetration at named health systems, whether condition coverage expands beyond the initial wedge without weakening clinical credibility, and whether the company can substantiate outcome claims with stronger third-party evidence than company-adjacent postings [TechCrunch, October 2026] [LinkedIn, 2026]. For investors, the appeal is clear, but so is the diligence burden: this is a category where workflow adoption and clinical proof matter at least as much as model performance.
One source, partially checked -- Relies primarily on TechCrunch reporting, with partial corroboration from RocketReach and company-linked materials; several operating and efficacy claims remain single-source or company-adjacent.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | ~$39.1M disclosed |
Company Overview
PUBLIC
Healthleap enters the frame first as a narrowly defined clinical workflow company, then as a broader inpatient-risk platform, and that chronology matters more than the marketing shorthand. The company was founded in 2022 and is headquartered in San Francisco, California, according to its Crunchbase profile [Crunchbase]. Its own website describes the business as building a clinical safety net for patients who might otherwise be missed, language that aligns with the later expansion of its product scope beyond nutrition-specific screening [Healthleap].
The milestone trail visible in public sources is concise but directionally useful. Healthleap's January 2022 pre-seed announcement centered on hospital malnutrition, which gives the company a clear initial wedge into acute-care operations [Healthleap]. By October 2026, the company website's careers page described Healthleap as an SF-based, hybrid-friendly company with more than $38 million raised, indicating a materially larger organization and financing base than at launch [Healthleap, October 2026]. Public materials reviewed for this section do not establish a legal entity name with enough confidence to include it here.
One source, partially checked -- Based primarily on Crunchbase and company website materials, with partial corroboration on headquarters and chronology.
The Product and the Stack
MIXED
Healthleap is selling a clinical AI platform into hospitals and health systems, with a product that reads electronic health records and flags inpatients who may need additional clinical attention [TechCrunch, October 2026]. The company started with hospital malnutrition, a narrow but operationally important workflow where missed cases can affect both patient outcomes and hospital economics, then broadened into a more general system for surfacing missed inpatient conditions such as malnutrition and delirium [TechCrunch, January 2022] [TechCrunch, October 2026]. That progression matters because it suggests the product is moving from a single-condition point solution toward a screening layer embedded in hospital decision-making, although the public record does not establish how deeply the software is integrated into clinical workflows at each health system [TechCrunch, October 2026].
The public evidence on performance is directionally promising but still thin. A LinkedIn-cited claim states that Healthleap's AI screening system was 88% more sensitive at flagging patients at high risk for malnutrition than nursing-administered manual screening, and that it surfaced higher-acuity patients as well [LinkedIn, 2026]. Separate LinkedIn-sourced material also claims hospital partners saw revenue improvement and shorter lengths of stay, but those statements do not come with a published study design, baseline definition, or health-system-level breakdown in the materials reviewed here [LinkedIn, 2026]. Investors should treat these as early product signals rather than settled clinical validation.
There is also some evidence of the technical posture and go-to-market packaging, even if the stack itself is only partially visible. Healthleap describes its mission as building "the safety net" for patients the system might otherwise miss, language that aligns with a screening and triage support product rather than a diagnostic replacement [Healthleap]. Its careers page described the company in October 2026 as SF-based and hybrid friendly, while open roles included a Founding Full-Stack Engineer and a Chief of Staff to the CEO, which points to continued product build-out and operational scaling rather than a fully mature software organization (inferred from job postings) [Healthleap, October 2026] [Welcome to the Jungle] [Ashby].
One source, partially checked -- Product scope is corroborated by two TechCrunch reports, but efficacy and technical-detail claims rely partly on company-linked and LinkedIn-sourced materials.
The Market They Are Entering
PUBLIC
Hospital AI is drawing capital because providers still run large parts of inpatient risk detection through labor-intensive workflows, while reimbursement and staffing pressure are pushing health systems to find earlier signals in the data they already collect [TechCrunch, January 2022] [TechCrunch, October 2026]. For Healthleap specifically, the public record supports demand around missed inpatient conditions, first through malnutrition screening and later through broader hospital record analysis, but it does not support a clean bottom-up TAM, SAM, or SOM calculation from named third-party market reports [TechCrunch, January 2022] [TechCrunch, October 2026].
The practical way to read the market is through the wedge Healthleap chose. The company entered through hospital malnutrition, a narrow clinical workflow with a defined buyer context, then expanded toward identifying missed inpatient conditions such as delirium and other cases where earlier recognition could change care plans or length of stay [TechCrunch, January 2022] [TechCrunch, October 2026]. That progression suggests an initial departmental entry point, followed by a broader enterprise software ambition inside hospitals and health systems, with the electronic health record as the system of record rather than a standalone data source [TechCrunch, October 2026].
Demand signals in the public evidence are more concrete than market sizing. TechCrunch reported that Healthleap grew from three hospital partners to more than 50 in the year before its October 2026 financing announcement, which indicates real provider willingness to test or adopt software aimed at inpatient case finding [TechCrunch, October 2026]. A LinkedIn-sourced outcome claim said the companys screening system was 88% more sensitive at flagging patients at high risk for malnutrition than manual nursing screening, but that evidence remains company-adjacent and should be treated as directional rather than market proof [LinkedIn, 2026].
The substitute markets matter because Healthleap is not selling into a blank space. Hospitals already address these problems through manual nursing screens, dietitian-led review, condition-specific protocols, and workflow tools embedded in or layered on top of electronic health records, so the relevant market is best understood as clinical decision support and inpatient workflow software rather than a standalone AI category [TechCrunch, January 2022] [TechCrunch, October 2026]. In that framing, the market tailwind is not simply interest in AI. It is provider willingness to pay for tools that can help surface overlooked patients without asking care teams to create entirely new documentation habits [TechCrunch, October 2026].
Regulatory and macro forces are present in the background, though the supplied public sources are thin on specifics. Hospitals face continuing pressure to improve throughput, document acuity accurately, and reduce avoidable days of stay, which aligns with Healthleaps public claims around revenue improvement and shorter stays for partners, though those claims again rest on LinkedIn material rather than independent outcomes reporting [LinkedIn, 2026]. The more conservative reading is that Healthleap sits in a market where adoption can accelerate if it shows measurable clinical and operational ROI inside existing hospital governance, but public evidence in this dataset does not yet establish the size of that prize with third-party precision [TechCrunch, October 2026].
| Market lens | What public sources support | Source basis |
|---|---|---|
| Initial wedge | Hospital malnutrition screening and intervention workflow | [TechCrunch, January 2022] |
| Expanded use case | Broader identification of missed inpatient conditions, including delirium | [TechCrunch, October 2026] |
| Buyer environment | Hospitals and health systems using EHR data to flag patients needing additional attention | [TechCrunch, October 2026] |
| Demand proxy | Growth from 3 hospital partners to more than 50 over the prior year | [TechCrunch, October 2026] |
The table shows why the market case is interesting even without a cited TAM figure. Public reporting supports a credible workflow pain point and a visible expansion path, but investors still need external market-sizing work before treating this as a fully quantified category opportunity.
One source, partially checked -- This section relies primarily on one independent public source, TechCrunch, with supplemental company-adjacent LinkedIn claims that are treated as directional rather than confirmed.
The Competitive Field
Landscape
MIXED Healthleap appears to sit between legacy clinical workflow inside the EHR and newer clinical-AI screening layers, with its current position defined more by a narrow inpatient wedge than by a fully mapped competitor set [TechCrunch, October 2026] [TechCrunch, January 2022].
The public record here is unusually thin on named rivals, which matters in itself. What is clear is the product moved from a hospital-malnutrition tool into a broader system that reads electronic health records and flags inpatients who may need additional clinical attention, including malnutrition and delirium [TechCrunch, January 2022] [TechCrunch, October 2026]. That places Healthleap in a practical buying contest against three kinds of alternatives: incumbent EHR workflows and manual screening processes already embedded in hospitals, point solutions built around a single condition or service line, and broader AI tools that promise earlier case finding across inpatient settings [TechCrunch, October 2026] [LinkedIn, 2026].
The incumbent benchmark is not another startup so much as the hospital's current operating model. TechCrunch's 2026 reporting frames the product as software that flags patients who may have missed or undiagnosed conditions, while a Healthleap-linked clinical claim says its screening system was 88% more sensitive than nursing-administered manual screening for malnutrition risk [TechCrunch, October 2026] [LinkedIn, 2026]. Even allowing for the weak corroboration on that performance figure, the competitive implication is straightforward: a hospital does not need to buy a rival startup to reject Healthleap, it can stay with nurse-led workflows, internal analytics, and existing EHR rule sets.
That makes Healthleap's edge today look real but somewhat perishable. The company has a visible wedge in malnutrition, a founder with clinical dietetics experience, and a reported footprint of more than 50 hospitals, including named health systems such as Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist, and Emory Healthcare [TechCrunch, October 2026] [Healthleap] [Crunchbase]. If those deployments are producing usable training data and day-to-day clinician workflow adoption, the company could build a defensible dataset and implementation playbook around hard-to-catch inpatient conditions. But the durability of that edge depends on whether Healthleap owns a repeatable integration and outcomes layer, or simply got to market early in one screening category. Public sources do not yet settle that question [TechCrunch, October 2026].
The exposure is easier to identify than the moat. Because no independent public source in this record names direct startup competitors, the strongest alternative remains the health system itself, especially large systems with analytics teams, existing Epic or Cerner workflows, and enough scale to build internal risk-flagging tools rather than license a separate platform [TechCrunch, October 2026]. Healthleap is also exposed if the category shifts from condition-specific detection to enterprise-wide clinical decision support sold through channels it does not control. In that scenario, the advantage would sit with the platform owner inside the hospital workflow, not with the screening specialist.
The most plausible 18-month scenario is a sorting between focused clinical-AI vendors that can show condition-level ROI and generalist tooling that cannot. Healthleap is the likely winner if hospitals continue to buy point solutions that prove operational and financial value service line by service line, because the company already has a reported malnutrition-origin wedge and a growing hospital base [TechCrunch, January 2022] [TechCrunch, October 2026]. The likely loser if hospitals decide they prefer internal builds or native EHR extensions is the broader class of standalone inpatient-screening startups, including Healthleap, because their distribution sits downstream of incumbent workflow control rather than inside it [TechCrunch, October 2026].
Opportunity
Upside case
PUBLIC The prize here is unusually large if Healthleap can turn a narrow clinical wedge into workflow infrastructure that hospitals rely on every day: the company is not selling a single point solution so much as a system for finding costly, missed inpatient problems inside the electronic health record [TechCrunch, January 2022] [TechCrunch, October 2026].
The headline opportunity is to become the default risk-detection layer for inpatient care, starting with malnutrition and moving into a broader set of conditions that are often missed early in a hospital stay [TechCrunch, January 2022] [TechCrunch, October 2026]. That outcome is still early rather than proven, but it is reachable for a simple reason: Healthleap has already shown a credible land-and-expand pattern, evolving from a nutrition-focused product built by Jemima Meyer into a broader platform deployed across more than 50 hospitals, according to TechCrunch's October 2026 reporting [TechCrunch, October 2026]. In hospital software, distribution tends to be the hardest part. Named deployments at large systems such as Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist, and Emory Healthcare matter because enterprise referenceability inside provider markets often travels through peer health systems rather than pure top-down marketing [TechCrunch, October 2026].
The upside can be framed through a few concrete scale paths rather than a single all-or-nothing outcome. Each path depends on execution, but each is grounded in what the company has already put into the market.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Clinical wedge to hospital-wide platform | Healthleap expands from malnutrition into a broader suite for missed inpatient conditions and becomes a standard layer used across multiple service lines within the same hospital | The October 2026 product shift toward identifying missed inpatient conditions, including malnutrition and delirium, gives the company a broader product surface inside existing accounts [TechCrunch, October 2026] | The company began with a focused use case, then broadened its scope after early deployment traction, a pattern that often fits enterprise clinical software adoption [TechCrunch, January 2022] [TechCrunch, October 2026] |
| Reference-account driven health-system rollout | A handful of marquee academic and integrated delivery networks validate outcomes strongly enough to accelerate adoption across peer institutions | Expansion from three hospital partners to more than 50 in the year before the October 2026 financing announcement suggests that customer acquisition may already be moving through health-system references and implementation repeatability [TechCrunch, October 2026] | Named customers include several large, recognizable systems, which gives Healthleap a base of institutional proof points if renewal and measured outcomes hold up [TechCrunch, October 2026] |
| Safety-net infrastructure for inpatient screening | Healthleap becomes the software layer hospitals use to catch conditions that manual screening misses, shifting buyer perception from a departmental tool to a quality and operations platform | Reported evidence from a Healthleap executive's LinkedIn profile said the AI system was 88% more sensitive at flagging high-risk malnutrition patients than manual nursing screening [LinkedIn, 2026] | If hospitals see better detection and shorter stays, the product can move from a clinical nice-to-have into an ROI-backed operations purchase, though the public evidence on outcomes remains thin today [LinkedIn, 2026] |
What starts to compound in this model is not consumer-style network effect, but clinical workflow entrenchment. A system that reads hospital records, flags patients for additional clinical attention, and expands condition coverage can become more valuable as it is trusted in more care pathways and adopted by more hospital teams within the same account [TechCrunch, October 2026]. The early signs of that flywheel are visible in the company's own product arc: a dietitian-built nutrition tool first, then a broader inpatient-risk platform; three partners first, then more than 50 hospitals; and active hiring across staff, engineering, and go-to-market functions after the latest financing announcement [TechCrunch, January 2022] [TechCrunch, October 2026] [Healthleap, October 2026] [Ashby] [Welcome to the Jungle] [Simplify Jobs]. If the product consistently finds missed cases earlier than manual workflows, each added condition and each successful deployment should make the next sale easier, because hospitals tend to prefer proven tools embedded into existing record systems over adding another disconnected clinical workflow [TechCrunch, October 2026].
The size of the win is harder to anchor precisely because no public market-sizing figure or close public comparable is provided in the available source set. Even so, the strategic end state is intelligible: if Healthleap becomes a broadly adopted inpatient decision-support platform across major health systems, the company could grow into a high-value healthcare software asset rather than a niche departmental application (scenario, not a forecast). The reason that statement is supportable, even without forcing a valuation number, is that the company is already selling to large provider organizations, has raised $39.1 million across pre-seed, seed, and Series A financing, and is positioning the product around missed conditions that affect both care quality and hospital economics [TechCrunch, January 2022] [TechCrunch, October 2026]. The upside case rests on whether those deployments convert into durable workflow ownership across more conditions and more hospital sites.
One source, partially checked -- Based primarily on TechCrunch's January 2022 and October 2026 reporting, with supplementary company and job-posting evidence for hiring and positioning; some outcome claims rely on LinkedIn and remain only partially corroborated.
Sources
Publicly reported
[TechCrunch, October 2026] Healthleap raises $38M for its AI that flags hospital patients who may need a closer look | https://techcrunch.com/2026/10/07/healthleap-raises-38m-for-its-ai-that-flags-hospital-patients-who-may-need-a-closer-look/
[TechCrunch, January 2022] HealthLeap raises $1.1M pre-seed to reduce malnutrition in hospitals with clinical AI assistant | https://techcrunch.com/2022/01/06/healthleap-raises-1-1m-pre-seed-to-reduce-malnutrition-in-hospitals-with-clinical-ai-assistant/
[Healthleap, October 2026] Healthleap Careers | https://healthleap.ai/careers
[LinkedIn, 2026] Tessa James, RD - Regional Vice President at HealthLeap AI | https://www.linkedin.com/in/tessa-james563/
[RocketReach, 2026] Josiah Meyer | RocketReach | https://rocketreach.co/
[Crunchbase] HealthLeap - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/healthleap-fe9b
[Healthleap] About HealthLeap, building the safety net for every patient | https://healthleap.ai/about
[Welcome to the Jungle] Founding Full-Stack Engineer | https://app.welcometothejungle.com/jobs/NN6xPBue
[Ashby] Chief of Staff to CEO | https://jobs.ashbyhq.com/healthleap/c8350844-94af-4445-9a51-d4071ab5c0a2
[Simplify Jobs] Event Marketing Lead | https://simplify.jobs/p/8c125f8e-54a5-4b8b-81be-be1f8d8856e/Event-Marketing-Lead
Articles about Healthleap
- Healthleap's AI Now Scans Records at 50 Hospitals for the Patients Clinicians Miss — The clinical AI startup, founded by a dietitian and a machine-learning founder, raised $38 million to expand from malnutrition screening to a broader 'safety net' for inpatients.